Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,968,559

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,968,559 protect, and when does it expire?

Patent 7,968,559 protects XERMELO and is included in one NDA.

This patent has thirty-three patent family members in twenty-four countries.

Summary for Patent: 7,968,559
Title:Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
Abstract: Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: ##STR00001##
Inventor(s): Devasagayaraj; Arokiasamy (Plainsboro, NJ), Jin; Haihong (Manalapan, NJ), Shi; Zhi-Cai (Monmouth Junction, NJ), Tunoori; Ashok (Princeton, NJ), Wang; Ying (Plainsboro, NJ), Zhang; Chengmin (Morristown, NJ)
Assignee: Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)
Application Number:12/754,341
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,968,559

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lexicon Pharms Inc XERMELO telotristat etiprate TABLET;ORAL 208794-001 Feb 28, 2017 RX Yes Yes   Start Trial   Start Trial THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,968,559

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064279   Start Trial
Australia 2007333120   Start Trial
Brazil PI0720270   Start Trial
Canada 2672233   Start Trial
Colombia 6220855   Start Trial
Denmark 2091940   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.